Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says Marketing Registration Of Jilixin Approved By NMPA
03/07/2025 11:31
July 3 (Reuters) - Hangzhou Jiuyuan Genetic Biopharmaceutical 2566.HK: MARKETING REGISTRATION OF JILIXIN APPROVED BY NMPA Further company coverage: 2566.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hangzhou Jiuyuan Genetic Biopharmaceutical
See all newsBrief: Hangzhou Jiuyuan Genetic Biopharmaceutical Approves H Share Repurchase Plan Up To RMB100 Mln
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says JY54 Injection Obtains NMPA Approval To Conduct Clinical Trials In China
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says JY47 Injection IND Application Obtains Clinical Trial Approval From NMPA
Brief: Hangzhou Jiuyuan Genetic Biopharmaceutical Says Marketing Application For Jikeqin Accepted By NMPA
Novo Nordisk cuts price of weight-loss drug Wegovy in China (updated)